Pharming Group PHARM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHARM is a good fit for your portfolio.
News
-
Pharming Group to report second quarter and first half 2024 financial results on August 1
-
Pharming Group to participate in June investor conferences
-
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
-
Pharming Group to participate in May investor conference
-
Pharming Group reports first quarter 2024 financial results and provides business update
Trading Information
- Previous Close Price
- €0.77
- Day Range
- €0.76–0.77
- 52-Week Range
- €0.72–1.31
- Bid/Ask
- €0.76 / €0.77
- Market Cap
- €517.54 Mil
- Volume/Avg
- 1.6 Mil / 4.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.35
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 382
- Website
- https://www.pharming.com
Comparables
Valuation
Metric
|
PHARM
|
NAMS
|
PHVS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.71 | 4.11 | 2.41 |
Price/Sales | 2.35 | 230.46 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PHARM
NAMS
PHVS
Financial Strength
Metric
|
PHARM
|
NAMS
|
PHVS
|
---|---|---|---|
Quick Ratio | 1.16 | 8.13 | 20.11 |
Current Ratio | 1.43 | 8.17 | 20.53 |
Interest Coverage | −2.66 | — | — |
Quick Ratio
PHARM
NAMS
PHVS
Profitability
Metric
|
PHARM
|
NAMS
|
PHVS
|
---|---|---|---|
Return on Assets (Normalized) | −3.79% | −39.62% | −29.37% |
Return on Equity (Normalized) | −8.05% | −46.06% | −31.42% |
Return on Invested Capital (Normalized) | −4.58% | −48.63% | −32.27% |
Return on Assets
PHARM
NAMS
PHVS
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Htnftyrw | Xhm | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Hlnrkjfs | Qgskgg | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Kjcjqdps | Qxdzz | $118.7 Bil | |||
Moderna Inc
MRNA
| Znprlfq | Qddmr | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Qhskpkmf | Dcvyd | $29.7 Bil | |||
argenx SE ADR
ARGX
| Nfxzldv | Bmzxn | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Bxhywktn | Czfs | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Ynxpyyftf | Nnltwt | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Rnrrlqpd | Rphh | $15.0 Bil | |||
Incyte Corp
INCY
| Rkyvjqnkr | Qgvmd | $13.5 Bil |